Hansa Biopharma, "Hansa" and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases.

CervoMed, a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that its oral investigational drug neflamapimod has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of frontotemporal dementia (FTD).

Lin BioScience a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting acute leukemia that have significant unmet medical needs, today announced that its lead pipeline, LBS-007

VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement.

Novartis announced today that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive,

Duality Biologics a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate therapeutics today announced the expansion of its ongoing collaboration with Adcendo ApS ("Adcendo")

Shorla Oncology, a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved IMKELDI (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers.

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference

Roche announced today the U.S. Food and Drug Administration (FDA) approval of a label expansion into biliary tract cancer (BTC) for the PATHWAY® anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* test.

Nanjing Leads Biolabs Co., Ltd. announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global intellectual property rights for the treatment of neuroendocrine cancer, has obtained Orphan Drug Designation